ArticleFrontiers in endocrinology2026
Familial investigation of two cases of pseudohypoparathyroidism.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Object: To report the clinical and genetic characteristics of patients diagnosed with pseudohypoparathyroidism (PHP) or inactivating parathyroid hormone (PTH)/PTHrP signaling disorders (iPPSD), and to provide insights for the diagnosis and management of this rare inherited metabolic disorder. Methods: This study focused on two patients diagnosed with PHP or iPPSD, aiming to investigate their clinical and genetic characteristics. Clinical manifestations and biochemical indicators of the two subjects were collected and analyzed. Whole-exome sequencing was employed to detect potential genetic mutations associated with the disorder. Additionally, pedigree analysis was performed to clarify the inheritance pattern of the identified mutation in the families of the two patients. Results: Both patients presented with recurrent seizures and Albright's hereditary osteodystrophy (AHO) features. Biochemical tests revealed consistent abnormalities in both subjects, including hypocalcemia, hyperphosphatemia, and elevated levels of PTH and thyroid-stimulating hormone (TSH). Whole-exome sequencing successfully isolated a specific four-nucleotide deletion (GACT) within exon 7 of the Conclusion: The symptoms of iPPSD are inconsistent and easily misidentified, which highlights the necessity of early genetic screening and PTH monitoring for patients with AHO-like physical traits or electrolyte imbalances. Precise molecular diagnosis is vital for ensuring effective and timely clinical intervention, as well as for preventing long-term complications associated with this rare metabolic disorder. This study provides valuable clinical and genetic data to enhance the understanding and management of PHP/iPPSD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.